Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

15 Jan 2007 12:52

Phytopharm PLC15 January 2007 Phytopharm plc Annual Information Update Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 28 December 2006, the following information has been published or made available to the public during the 12 months ended 12 January 2007, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets. For the purpose of this update, only references to the information are provided. Full copies of each item can be found at the locations specified below. In accordance with the provisions of Article 27.3 of the Prospectus Directive Regulations, we confirm that to the best of our knowledge, information relating to 'Holdings in Company' and 'Director/PDMR Shareholdings' is up to date at the date of this announcement, but it is acknowledged that such disclosures may, at any time, become out of date, due to changing circumstances. 1. Announcements made via Regulatory Information Services All documents listed below were published via a regulatory information service on the dates indicated: Date of publication Title 10 January 2007 Director/PDMR shareholding10 January 2007 Director/PDMR shareholding 9 January 2007 Board changes19 December 2006 Notification of total voting rights10 November 2006 Director/PDMR shareholding 8 November 2006 Preliminary results for the year ended 31 August 2006 1 November 2006 Block listing interim review27 October 2006 Notification of results18 September 2006 Block listing interim review 5 September 2006 Board changes21 July 2006 Board appointment 5 June 2006 Board appointment19 May 2006 Holding(s) in company11 May 2006 Director/PDMR shareholding11 May 2006 Director/PDMR shareholding 8 May 2006 Interim results 3 May 2006 Block listing interim review27 April 2006 Holding(s) in company27 April 2006 Holding(s) in company26 April 2006 Advisor appointment24 April 2006 Product launch10 April 2006 Research update30 March 2006 Notice of results17 March 2006 Block listing interim review30 January 2006 Second price monitoring extension30 January 2006 Price monitoring extension24 January 2006 Results of AGM 2. Documents despatched to shareholders The following documents have been despatched by the Company to holders of its securities during the year: 27 December 2006 - Annual Report 2006 1 June 2006 - Interim Report 2006 3. Documents field at Companies House The Company has submitted the following Filings to Companies House: 11 January 2007 Form 288(a) Appointment of Director Mr Piers Morgan11 January 2007 Form 288(b) Terminating appointment of Director - Dr Richard Dixey 5 December 2006 Form 363 Annual Return 6 September 2006 Form 288(b) Terminating appointment of Director - Dr Trevor Flanagan 6 September 2006 Form 288(b) Terminating appointment of Director - Mr Gordon Stevens24 July 2006 Form 288(a) Appointment of Director - Dr Peter Blower 8 June 2006 Form 288(a) Appointment of Director - Mr Alexander Morrison24 January 2006 Registration of special resolutions passed at AGM Copies of these documents can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ (Telephone 0870 3333 636, email at enquiries@companies-house.gov.uk) or, if you are a registered user, through Companies House Direct at www.companies-house.gov.uk The Company's annual report and accounts 2006 (published on 28 December 2006) and Interim Report 2005 (published on 1 June 2006) can be found on the Company's website as can the Interim Results announcement for the six months ended 28 February 2006 (published on 8 May 2006) and the Preliminary Results Announcement (published on 8 November 2006), The Company's website is www.phytopharm.com. Copies of all documents referred to above are also available for inspection at the Company's registered office (Corpus Christi House, 9 West Street, Godmanchester, Cambs PE29 2HY, United Kingdom) during normal business hours or by request from the Company Secretary. For further information, please contact: Zoe McGowan, Company Secretary Phytopharm plc Tel No: +44 (0)1480 437697 Further information, about Phytopharm can be found on the Company's website www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing
21st Jan 202111:05 amRNSResult of AGM
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company
26th Aug 202011:55 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.